-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, Chongqing Kerui Nanhai Pharmaceutical Co.
, Ltd.
entered the administrative examination and approval stage with the generic 4 types of Alogliptin benzoate tablets and is expected to be approved
.
According to Meinenet, in 2020, the total sales of Alogliptin benzoate tablets in the terminals of Chinese public medical institutions and the terminals of physical pharmacies in Chinese cities are nearly 200 million yuan, and only Takeda Pharmaceuticals is on sale
.
, Ltd.
entered the administrative examination and approval stage with the generic 4 types of Alogliptin benzoate tablets and is expected to be approved
.
According to Meinenet, in 2020, the total sales of Alogliptin benzoate tablets in the terminals of Chinese public medical institutions and the terminals of physical pharmacies in Chinese cities are nearly 200 million yuan, and only Takeda Pharmaceuticals is on sale
.
Alogliptin belongs to the class of dipeptidyl peptidase 4 inhibitors (DPP-4 inhibitors) and is used to treat adult type 2 diabetes
.
The product was developed by Takeda Pharmaceuticals and was approved for import in China in 2013.
It is a category B product in the 2020 National Medical Insurance Catalog
.
.
The product was developed by Takeda Pharmaceuticals and was approved for import in China in 2013.
It is a category B product in the 2020 National Medical Insurance Catalog
.
Sales of Alogliptin Benzoate Tablets in Chinese Public Medical Institutions and Chinese Urban Entity Pharmacies (Unit: 100 million yuan)
Source: Mi Nei Net Database
According to data from Menet.
com, in 2020, the total sales of Alogliptin Benzoate Tablets in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals and Chinese urban physical pharmacies terminals will be close to 200 million yuan, only Takeda Pharmaceuticals is on sale
.
It is worth mentioning that the terminal growth rate of this product in public medical institutions in Chinese cities is staggering, and the growth rate has exceeded 50% in recent years
.
com, in 2020, the total sales of Alogliptin Benzoate Tablets in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals and Chinese urban physical pharmacies terminals will be close to 200 million yuan, only Takeda Pharmaceuticals is on sale
.
It is worth mentioning that the terminal growth rate of this product in public medical institutions in Chinese cities is staggering, and the growth rate has exceeded 50% in recent years
.
Source: One-click search on Mi Nei.
com
com
At present, there are 11 manufacturers of alogliptin benzoate tablets
.
By the end of 2019, after Yabao won the first imitation products, CSPC Pharmaceutical Europa, Guangdong East Sunshine Pharmaceutical, Sinopharm Guorui Pharmaceutical and other companies have been approved, 10 new domestic enterprises are classified report If the product is approved, it is deemed to have been reviewed
.
In addition, 6 companies including Chongqing Kerui Nanhai Pharmaceutical and Ruiyang Pharmaceutical are under review and approval (in the drug review center)
.
.
By the end of 2019, after Yabao won the first imitation products, CSPC Pharmaceutical Europa, Guangdong East Sunshine Pharmaceutical, Sinopharm Guorui Pharmaceutical and other companies have been approved, 10 new domestic enterprises are classified report If the product is approved, it is deemed to have been reviewed
.
In addition, 6 companies including Chongqing Kerui Nanhai Pharmaceutical and Ruiyang Pharmaceutical are under review and approval (in the drug review center)
.
Data source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
Note: Meinenet China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 cities and above cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
.
The above sales are calculated based on the average retail price of the product at the terminal
.
A few days ago, Chongqing Kerui Nanhai Pharmaceutical Co.
, Ltd.
entered the administrative examination and approval stage with the generic 4 types of Alogliptin benzoate tablets and is expected to be approved
.
According to Meinenet, in 2020, the total sales of Alogliptin benzoate tablets in the terminals of Chinese public medical institutions and the terminals of physical pharmacies in Chinese cities are nearly 200 million yuan, and only Takeda Pharmaceuticals is on sale
.
, Ltd.
entered the administrative examination and approval stage with the generic 4 types of Alogliptin benzoate tablets and is expected to be approved
.
According to Meinenet, in 2020, the total sales of Alogliptin benzoate tablets in the terminals of Chinese public medical institutions and the terminals of physical pharmacies in Chinese cities are nearly 200 million yuan, and only Takeda Pharmaceuticals is on sale
.
Alogliptin belongs to the class of dipeptidyl peptidase 4 inhibitors (DPP-4 inhibitors) and is used to treat adult type 2 diabetes
.
The product was developed by Takeda Pharmaceuticals and was approved for import in China in 2013.
It is a category B product in the 2020 National Medical Insurance Catalog
.
.
The product was developed by Takeda Pharmaceuticals and was approved for import in China in 2013.
It is a category B product in the 2020 National Medical Insurance Catalog
.
Sales of Alogliptin Benzoate Tablets in Chinese Public Medical Institutions and Chinese Urban Entity Pharmacies (Unit: 100 million yuan)
Source: Mi Nei Net Database
According to data from Menet.
com, in 2020, the total sales of Alogliptin Benzoate Tablets in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals and Chinese urban physical pharmacies terminals will be close to 200 million yuan, only Takeda Pharmaceuticals is on sale
.
It is worth mentioning that the terminal growth rate of this product in public medical institutions in Chinese cities is staggering, and the growth rate has exceeded 50% in recent years
.
com, in 2020, the total sales of Alogliptin Benzoate Tablets in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals and Chinese urban physical pharmacies terminals will be close to 200 million yuan, only Takeda Pharmaceuticals is on sale
.
It is worth mentioning that the terminal growth rate of this product in public medical institutions in Chinese cities is staggering, and the growth rate has exceeded 50% in recent years
.
Source: One-click search on Mi Nei.
com
com
At present, there are 11 manufacturers of alogliptin benzoate tablets
.
By the end of 2019, after Yabao won the first imitation products, CSPC Pharmaceutical Europa, Guangdong East Sunshine Pharmaceutical, Sinopharm Guorui Pharmaceutical and other companies have been approved, 10 new domestic enterprises are classified report If the product is approved, it is deemed to have been reviewed
.
In addition, 6 companies including Chongqing Kerui Nanhai Pharmaceutical and Ruiyang Pharmaceutical are under review and approval (in the drug review center)
.
.
By the end of 2019, after Yabao won the first imitation products, CSPC Pharmaceutical Europa, Guangdong East Sunshine Pharmaceutical, Sinopharm Guorui Pharmaceutical and other companies have been approved, 10 new domestic enterprises are classified report If the product is approved, it is deemed to have been reviewed
.
In addition, 6 companies including Chongqing Kerui Nanhai Pharmaceutical and Ruiyang Pharmaceutical are under review and approval (in the drug review center)
.
Data source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
Note: Meinenet China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 cities and above cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
.
The above sales are calculated based on the average retail price of the product at the terminal
.
A few days ago, Chongqing Kerui Nanhai Pharmaceutical Co.
, Ltd.
entered the administrative examination and approval stage with the generic 4 types of Alogliptin benzoate tablets and is expected to be approved
.
According to Meinenet, in 2020, the total sales of Alogliptin benzoate tablets in the terminals of Chinese public medical institutions and the terminals of physical pharmacies in Chinese cities are nearly 200 million yuan, and only Takeda Pharmaceuticals is on sale
.
, Ltd.
entered the administrative examination and approval stage with the generic 4 types of Alogliptin benzoate tablets and is expected to be approved
.
According to Meinenet, in 2020, the total sales of Alogliptin benzoate tablets in the terminals of Chinese public medical institutions and the terminals of physical pharmacies in Chinese cities are nearly 200 million yuan, and only Takeda Pharmaceuticals is on sale
.
Alogliptin belongs to the class of dipeptidyl peptidase 4 inhibitors (DPP-4 inhibitors) and is used to treat adult type 2 diabetes
.
The product was developed by Takeda Pharmaceuticals and was approved for import in China in 2013.
It is a category B product in the 2020 National Medical Insurance Catalog
.
Medicine, medicine, medicine.
The product was developed by Takeda Pharmaceuticals and was approved for import in China in 2013.
It is a category B product in the 2020 National Medical Insurance Catalog
.
Sales of Alogliptin Benzoate Tablets in Chinese Public Medical Institutions and Chinese Urban Entity Pharmacies (Unit: 100 million yuan)
Source: Mi Nei Net Database
According to data from Menet.
com, in 2020, the total sales of Alogliptin Benzoate Tablets in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals and Chinese urban physical pharmacies terminals will be close to 200 million yuan, only Takeda Pharmaceuticals is on sale
.
It is worth mentioning that the terminal growth rate of this product in public medical institutions in Chinese cities is staggering, and the growth rate has exceeded 50% in recent years
.
Hospital hospital hospital pharmacy pharmacy pharmacycom, in 2020, the total sales of Alogliptin Benzoate Tablets in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals and Chinese urban physical pharmacies terminals will be close to 200 million yuan, only Takeda Pharmaceuticals is on sale
.
It is worth mentioning that the terminal growth rate of this product in public medical institutions in Chinese cities is staggering, and the growth rate has exceeded 50% in recent years
.
Source: One-click search on Mi Nei.
com
com
At present, there are 11 manufacturers of alogliptin benzoate tablets
.
By the end of 2019, after Yabao won the first imitation products, CSPC Pharmaceutical Europa, Guangdong East Sunshine Pharmaceutical, Sinopharm Guorui Pharmaceutical and other companies have been approved, 10 new domestic enterprises are classified report If the product is approved, it is deemed to have been reviewed
.
In addition, 6 companies including Chongqing Kerui Nanhai Pharmaceutical and Ruiyang Pharmaceutical are under review and approval (in the drug review center)
.
Enterprise business enterprise.
By the end of 2019, after Yabao won the first imitation products, CSPC Pharmaceutical Europa, Guangdong East Sunshine Pharmaceutical, Sinopharm Guorui Pharmaceutical and other companies have been approved, 10 new domestic enterprises are classified report If the product is approved, it is deemed to have been reviewed
.
In addition, 6 companies including Chongqing Kerui Nanhai Pharmaceutical and Ruiyang Pharmaceutical are under review and approval (in the drug review center)
.
Data source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
Note: Meinenet China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 cities and above cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
.
The above sales are calculated based on the average retail price of the product at the terminal
.
